Genovis (GENO) Q3 2025 earnings summary

Executive summary

• Net sales for Q3 2025 were SEK 27.5 million, down 13% year-over-year, mainly due to timing effects from large customer orders and a volatile service business.

• Acquisition of the remaining 75% of Sequrna AB completed in July 2025, strengthening the genomics product portfolio.

• Organic sales to large pharma and biopharma customers grew 30% in Q3 and 19% for the first nine months, adjusted for currency effects.

• A significant EUR 1 million order was received in October from a global pharmaceutical company for antibody conjugation technology.

Financial highlights

• Q3 2025 net sales: SEK 27.5 million (down 13% year-over-year, -7% adjusted for currency).

• Q3 EBITDA: SEK 6.9 million (down from SEK 10.8 million), margin 25% (30% adjusted for non-recurring costs).

• Q3 EBIT: SEK 3.4 million (down from SEK 8.5 million).

• Q3 EPS: SEK 0.12 (down from SEK 0.21).

• Q3 cash flow from operations: SEK 10.9 million (up from SEK 0.7 million).

• 9M 2025 net sales: SEK 88.7 million (up 8% year-over-year, 12% adjusted for currency).

• 9M EBITDA: SEK 21.8 million (down from SEK 22.9 million).

• 9M EBIT: SEK 13.2 million (down from SEK 16.6 million).

• 9M EPS: SEK 0.25 (down from SEK 0.43).

• 9M cash flow from operations: SEK 16.1 million (down from SEK 18.5 million).

Outlook and guidance

• Management expects a recovery in biotech customer activity, especially in the U.S., with a strong start to Q4 and increased order flow.

• The company is positioned for further advances in new products and sales in 2025, despite ongoing macroeconomic and geopolitical uncertainties.